to cell-surface receptors (1) . The existence of a liver receptor responsible for removing a2M-proteinase complexes from the circulation was first suspected in early studies where it was observed that a2M-trypsin complexes were rapidly eliminated from the dog circulation. The a2M receptor was subsequently purified by affinity chromatography (2, 3) , and protein sequencing studies revealed it to be identical to the LDL receptor-related protein (LRP) (4). LRP was initially identified when a cDNA was cloned by a homology screening approach (5) . Because the encoded protein resembled the LDL receptor and was able to bind apoE-enriched lipoproteins (6) , LRP was suspected of being responsible for the catabolism of lipoprotein "remnants." These particles are generated from two key lipoproteins, chylomicrons and very low density lipoproteins (VLDLs), which are responsible for transporting triglycerides and other lipids from the intestine or liver to other tissues, such as muscle. During this process, chylomicrons or VLDLs are modified by hydrolases, such as lipoprotein lipase, to form remnants, which are then catabolized by a receptor (or receptors) present in the liver. Even though the LDL receptor is able to mediate the clearance of remnants, genetic evidence (7) suggests that another liver receptor is also involved in this process, and available evidence suggests that LRP may be this receptor.
It is now apparent that LRP is responsible for mediating the cellular internalization of many ligands, including proteinases, proteinase-inhibitor complexes, lipoproteins, a bacterial toxin, and a minor-group human rhinovirus. In addition to its role in the hepatic removal of several ligands from the plasma, LRP is also essential for embryonic development (8). This review will summarize the structure of LRP, its role in the catabolism of lipoproteins and proteinases, and its potential role in pathophysiological processes. ' for binding the ligands apolipoproteins B and E (9).
The most recently discovered member of the LDL receptor family is the very low density lipoprotein (VLDL) receptor. This receptor was so named because it was found to bind apoE-containing lipoproteins such as VLDL with high affinity, but with weaker affinity to LDL (10). The primary sequence and gene structure of this receptor is similar to that of the LDL receptor, except that the VLDL receptor gene contains an extra exon that encodes an additional cysteine-rich repeat sequence within the ligand binding domain (11) . A cDNA encoding a variant form of the VLDL receptor that lacks the 0-linked sugar domain has also (14) .
LRP is considerably larger than either the LDL receptor or the VLDL receptor. The LRP cytoplasmic domain contains 100 amino acid residues with two copies of the NPXY sequence.
The 0-linked sugar domain of the LDL receptor is replaced by six growth factorlike repeats in LRP. LRP contains a total of 22 growth factor repeats and 31 complement-type repeats arranged into four clusters, and is synthesized as a single-chain precursor that is cleaved in the trans Golgi to a 515 kDa heavy chain and an 85 kDa light chain (15 Because the stimulation was blocked by an antibody against LRP (6), these studies suggest that LRP mediates the uptake of chylomicron remnantlike particles, but only after they have been enriched by excess apoE. This requirement for excess apoE led to a secretion-recapture model for remnant uptake in the liver (25, 27) . In this model, remnant particles are envisioned to enter the sinusoidal space of the liver. The remnant particles are thought to adhere to extracellular proteoglycans, and are exposed to high concentrations of apoE secreted by hepatocytes.
After enrichment of the remnants with apoE, they are active ligands for LRP, which can then mediate their internalization and subsequent degradation. (Fig. 2) . The catabolism of 1251-labeled a2M-proteinase complex (a2M*), which is known to be mediated by LRP, was unaffected by this treatment (Fig. 2) and PAl-i are both able to inhibit the binding of 1251-labeled uPA:PAI-1 complexes to LRP in in vitro binding assays (37, 38) . To determine whether uPAR is internalized along with LRP, a soluble form of uPAR that lacks the glycosyl-phosphatidylinositol-anchor was used (39) . 1251_ soluble uPAR in the absence or presence of pro-uPA was not internalized by Chinese hamster ovary cells. However, in the presence of uPA:PAI-i complexes, significant uptake of '251-soluble uPAR was detected, which could be blocked by RAP (39) . This suggests that uPA:PAI-1 efficiently cross-links uPAR to LRP, which then mediates internalization of the entire complex. This does not occur with pro-uPA alone. Within the endosome, the ligand dissociates from the receptor while LRP is recycled back to the cell surface. At this time, the fate of uPAR is not known, but very likely it also recycles back to the cell surface. and by RAP, indicating that LRP is mediating this process. To investigate the form of uPA internalized, the ligand was recovered from the cells after internalization and evaluated by SDS polyacrylamide gel electrophoresis (38) . These experiments revealed that single-chain uPA was internalized and did not require activation to the two-chain molecule or subsequent complex formation with PAl-i for internalization to occur. Thus, LRP appears capable of mediating the cellular internalization of pro-uPA directly. The involvement of uPAR in catabolism of pro-uPA has been recently examined.
Role of lipoprotein lipase in LRP-
Nykjr et al. (37) found that soluble uPAR blocked the binding of pro-uPA to LRP, suggesting that uPAR may protect pro-uPA from LRP-mediated internalization.
The suggestion that uPAR protects pro-uPA from LRP-mediated internalization is an attractive hypothesis, and explains the observation that in certain cell types pro-uPA remains on the cell surface for long periods of time (40) . On the other hand, Hep G2 cells (38) and fibroblasts rapidly internalize pro-uPA in a process mediated by LRP. This may result from low levels of uPAR and high levels of LRP within these cells. Also, because the kringle domain of uPA is known to bind to heparin (41) , pro-uPA may interact with cell-surface proteoglycans, which could facilitate its transfer to LRP for subsequent internalization and degradation in a mechanism that is somewhat analogous to the participation of cell-surface proteoglycans in the LRP-mediated catabolism of lipoprotein lipase (29) . Additional experiments are required to determine whether or not this is the case. Summarizing all of the available evidence, the predominant role for LRP is to mediate the internalization of free pro-uPA or that which may be associated with proteoglycans, whereas the pro-uPA associated with uPAR is localized on the cell surface and able to mediate cell-surface plasminogen activation. It is not until PM-i associates with uPAR-bound uPA that the uPA:PAI-1 is internalized in a process mediated by LRP. During this latter process, it appears that uPAR is also recycled through the endosomal pathway along with the uPA: PAl-i complex and is delivered back to the cell surface in an unoccupied state.
Role of LRP in mediating the cellular internalization and degradation of tPA Significant progress has been made recently in thrombolytic therapy, and tPA has been shown to be an effective thrombolytic agent (42) . However, the effectiveness of this agent is hampered somewhat by its rapid clearance from the circulation (42) . Three distinct mechanisms have been identified that are responsible for the removal of t-PA from the plasma (43). The first mechanism involves recognition of the mannose-rich oligosaccharide found on the kringle 1 domain of t-PA by the mannose receptor, which is found primarily on endothelial cells. The second mechanism for t-PA clearance occurs after reaction oft-PA with its inhibitor, plasminogen activator inhibitor type 1 (PM-i by an hepatic receptor (43, 45) . RAP completely blocks the cellular uptake and degradation of 125I-labeled tPA in cultured fibroblasts (45) , which suggests that LRP is responsible for tPA catabolism.
This was confirmed by demonstrating that fibroblasts that lack LRP do not internalize 1251-labeled tPA (45) . Together, these data suggest that LRP mediates the cellular uptake of tPA, leading to its degradation.
To investigate the role of LRP in mediating the in vivo clearance of tPA in rats, the effect of RAP on the rate of '251-labeled tPA removal from the circulation was investigated (43 
